Thornburg Investment Management Inc. Raises Holdings in Glaukos Co. (NYSE:GKOS)

Thornburg Investment Management Inc. grew its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 18.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,583 shares of the medical instruments supplier's stock after acquiring an additional 7,072 shares during the period. Thornburg Investment Management Inc. owned about 0.08% of Glaukos worth $6,835,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of GKOS. IFP Advisors Inc purchased a new position in shares of Glaukos during the fourth quarter valued at about $43,000. Asset Planning Inc purchased a new position in Glaukos during the fourth quarter valued at $90,000. CoreCap Advisors LLC boosted its holdings in shares of Glaukos by 36.4% during the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after buying an additional 200 shares in the last quarter. Picton Mahoney Asset Management bought a new stake in shares of Glaukos during the 4th quarter valued at $125,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of Glaukos in the 4th quarter worth about $153,000. Hedge funds and other institutional investors own 99.04% of the company's stock.

Insiders Place Their Bets

In other news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.80% of the stock is currently owned by company insiders.

Glaukos Price Performance

GKOS traded down $1.29 during trading hours on Friday, hitting $95.90. The company's stock had a trading volume of 216,886 shares, compared to its average volume of 692,961. The stock has a market cap of $5.48 billion, a price-to-earnings ratio of -33.34 and a beta of 0.83. The business's 50-day moving average price is $93.51 and its 200-day moving average price is $124.97. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12 month low of $77.10 and a 12 month high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. During the same quarter last year, the firm earned ($0.70) EPS. The firm's revenue for the quarter was up 24.6% compared to the same quarter last year. Sell-side analysts expect that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GKOS has been the topic of several analyst reports. Needham & Company LLC dropped their target price on Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Mizuho reduced their price objective on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 16th. Wells Fargo & Company downgraded shares of Glaukos from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $160.00 to $86.00 in a research note on Thursday, May 1st. Stephens cut their price target on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Finally, Stifel Nicolaus cut their target price on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Glaukos currently has an average rating of "Moderate Buy" and a consensus price target of $134.67.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.